{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:59:06Z","timestamp":1792418346527,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12029-025-01299-5","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T22:10:48Z","timestamp":1755641448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neutrophil-to-Lymphocyte Ratio (NLR) as a Predictive Biomarker in Advanced Hepatocellular Carcinoma Treated with First-Line Immunotherapy"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-8118","authenticated-orcid":false,"given":"Tiago","family":"Felismino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luanna","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matheus","family":"Barroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Maccali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Coimbra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"issue":"2","key":"1299_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2024.102446","volume":"15","author":"SP Singh","year":"2025","unstructured":"Singh SP, Madke T, Chand P. Global epidemiology of hepatocellular carcinoma. J Clin Exp Hepatol. 2025;15(2): 102446.","journal-title":"J Clin Exp Hepatol"},{"issue":"10360","key":"1299_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"issue":"3","key":"1299_CR3","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393.","journal-title":"J Hepatol"},{"issue":"15","key":"1299_CR4","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42(15):1830\u201350.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1299_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","volume":"36","author":"A Vogel","year":"2025","unstructured":"Vogel A, Chan SL, Dawson LA, Kelley RK, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2025;36(5):491\u2013506.","journal-title":"Ann Oncol"},{"issue":"11","key":"1299_CR6","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-21-4000","volume":"28","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, et al. Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized phase III trials. Clin Cancer Res. 2022;28(11):2297\u2013305.","journal-title":"Clin Cancer Res"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.3332\/ecancer.2024.1748","volume":"18","author":"LG da Fonsecaa","year":"2024","unstructured":"da Fonsecaa LG, de Melob MAZ, da Silveirac THM, Yamamotod VJ, Hashizumee PHS, Sabbagaf J. Prognostic role of albumin-bilirubin (ALBI) score and Child-Pugh classification in patients with advanced hepatocellular carcinoma under systemic treatment. Ecancermedicalscience. 2024;18:1748.","journal-title":"Ecancermedicalscience"},{"issue":"10","key":"1299_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda H, Johnson PJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4(10): 100557.","journal-title":"JHEP Rep"},{"key":"1299_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1393925","volume":"15","author":"B Pei","year":"2024","unstructured":"Pei B, Zhang J, Lai L, Chen H. Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2024;15: 1393925.","journal-title":"Front Immunol"},{"key":"1299_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100445","author":"M Stares","year":"2022","unstructured":"Stares M, Ding TE, Stratton C, Thomson F, Baxter M, Cagney H, et al. Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer. ESMO Open. 2022. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100445.","journal-title":"ESMO Open"},{"issue":"3","key":"1299_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/jso.20329","volume":"91","author":"SR Walsh","year":"2005","unstructured":"Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005;91(3):181\u20134.","journal-title":"J Surg Oncol"},{"key":"1299_CR12","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.2147\/JHC.S322289","volume":"8","author":"B Gok Yavuz","year":"2021","unstructured":"Gok Yavuz B, Hasanov E, Lee SS, Mohamed YI, Curran MA, Koay EJ, et al. Current landscape and future directions of biomarkers for immunotherapy in hepatocellular carcinoma. J Hepatocell Carcinoma. 2021;8:1195\u2013207.","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"1299_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50378-9","volume":"14","author":"K Ohashi","year":"2024","unstructured":"Ohashi K, Nishito Y, Fukuda H, Sadahiro R, Yoshida Y, Watanabe S-i, et al. Neutrophil-to-lymphocyte ratio is a prognostic factor reflecting immune condition of tumor microenvironment in squamous cell lung cancer. Sci Rep. 2024;14(1): 429.","journal-title":"Sci Rep"},{"issue":"4","key":"1299_CR14","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.21037\/tcr-20-3237","volume":"10","author":"S Lin","year":"2021","unstructured":"Lin S, Hu S, Ran Y, Wu F. Neutrophil-to-lymphocyte ratio predicts prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2021;10(4):1667\u201378.","journal-title":"Transl Cancer Res"},{"key":"1299_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1211399","volume":"14","author":"C Xu","year":"2023","unstructured":"Xu C, Wu F, Du L, Dong Y, Lin S. Significant association between high neutrophil-lymphocyte ratio and poor prognosis in patients with hepatocellular carcinoma: a systematic review and meta-analysis. Front Immunol. 2023;14: 1211399.","journal-title":"Front Immunol"},{"issue":"5","key":"1299_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1136\/gutjnl-2018-316510","volume":"68","author":"CJ Lim","year":"2019","unstructured":"Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916\u201327.","journal-title":"Gut"},{"issue":"2","key":"1299_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29485","volume":"96","author":"Y Liu","year":"2024","unstructured":"Liu Y, Kim ES, Guo H. Hepatitis B virus-related hepatocellular carcinoma exhibits distinct intratumoral microbiota and immune microenvironment signatures. J Med Virol. 2024;96(2): e29485.","journal-title":"J Med Virol"},{"issue":"7854","key":"1299_CR18","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592(7854):450\u20136.","journal-title":"Nature"},{"issue":"1","key":"1299_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48(1):73\u201385.","journal-title":"Biometrics"},{"issue":"2","key":"1299_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263298","volume":"17","author":"N Ratnasari","year":"2022","unstructured":"Ratnasari N, Lestari P, Renovaldi D, Raditya Ningsih J, Qoriansas N, Wardana T, et al. Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of hepatocellular carcinoma patients. PLoS One. 2022;17(2): e0263298.","journal-title":"PLoS One"},{"key":"1299_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-117","volume":"14","author":"WK Xiao","year":"2014","unstructured":"Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014;14: 117.","journal-title":"BMC Cancer"},{"issue":"20","key":"1299_CR22","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894\u2013905.","journal-title":"N Engl J Med"},{"issue":"8","key":"1299_CR23","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8): EVIDoa2100070.","journal-title":"NEJM Evid"},{"issue":"7","key":"1299_CR24","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","volume":"22","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22(7):977\u201390.","journal-title":"Lancet Oncol"},{"key":"1299_CR25","doi-asserted-by":"crossref","unstructured":"Galle PR, Decaens T, Kudo M, Qin S, Fonseca L, Sangro B, et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): first results from CheckMate 9DW. J Clin Oncol. 2024;42(17_suppl):LBA4008\u2013LBA.","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA4008"},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, Georges D, Ibrahim AS, Zheng R, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"issue":"12","key":"1299_CR27","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.4254\/wjh.v7.i12.1708","volume":"7","author":"S Ashtari","year":"2015","unstructured":"Ashtari S, Pourhoseingholi MA, Sharifian A, Zali MR. Hepatocellular carcinoma in Asia: prevention strategy and planning. World J Hepatol. 2015;7(12):1708\u201317.","journal-title":"World J Hepatol"},{"issue":"29","key":"1299_CR28","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.3748\/wjg.v16.i29.3603","volume":"16","author":"W Blonski","year":"2010","unstructured":"Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16(29):3603\u201315.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1299_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2394268","volume":"20","author":"S Sun","year":"2024","unstructured":"Sun S, Li W, Guo X, Chen J. Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors. Hum Vaccin Immunother. 2024;20(1): 2394268.","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"1299_CR30","doi-asserted-by":"publisher","first-page":"19583","DOI":"10.1038\/s41598-024-68048-9","volume":"14","author":"J Du","year":"2024","unstructured":"Du J, Huang Z. NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma. Sci Rep. 2024;14(1):19583.","journal-title":"Sci Rep"},{"issue":"4_suppl","key":"1299_CR31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.504","volume":"41","author":"L Wu","year":"2023","unstructured":"Wu L, Fulgenzi CAM, D\u2019Alessio A, Chon HJ, Kudo M, Sch\u00f6nlein M, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers in unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (atezo-bev). J Clin Oncol. 2023;41(4_suppl): 504.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1299_CR32","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41416-021-01445-3","volume":"125","author":"PJ Johnson","year":"2021","unstructured":"Johnson PJ, Dhanaraj S, Berhane S, Bonnett L, Ma YT. The prognostic and diagnostic significance of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: a prospective controlled study. Br J Cancer. 2021;125(5):714\u20136.","journal-title":"Br J Cancer"},{"issue":"4","key":"1299_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195042","volume":"13","author":"YA Vano","year":"2018","unstructured":"Vano YA, Oudard S, By MA, T\u00eatu P, Thibault C, Aboudagga H, et al. Optimal cut-off for neutrophil-to-lymphocyte ratio: fact or fantasy? A prospective cohort study in metastatic cancer patients. PLoS One. 2018;13(4): e0195042.","journal-title":"PLoS One"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01299-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01299-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T17:15:42Z","timestamp":1757438142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01299-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01299-5","relation":{},"ISSN":["1941-6628","1941-6636"],"issn-type":[{"value":"1941-6628","type":"print"},{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"12 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of A.C.Camargo Cancer Center (date 20\u201302-2024\/No. 3546\/23).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was waived due to the retrospective nature of the study and the use of de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}